Pricing Log in Create free account
Saturday 17 October 2026 Export DOCS’s income statement to Excel — free account

Doximity, Inc.

DOCS Healthcare Health Information Services

Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025. In the quarter to June 2026, revenue grew 7.34%, EPS fell 53.6% and free cash flow fell 34.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

30.97 0.53 −1.68%
Market cap
$5.6B
P/E
34.8×
Fwd P/E
26.2×
Dividend yield
—
F-score
5/9
Altman Z
17.11
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 1 1 2 2 1 2 1 1 3 3 1
Insider Ownership 32.89%

Capital & Financial Ratios $m

Market Cap 5,610.00
Revenue 655.57
Net Income 167.05
Free Cash Flow 297.03
Net Debt (687.79)
Current Ratio 6.08 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 34.80
Fwd P/E 26.20
P/S ratio 8.62
P/B ratio 6.17 (above 6: high)
Past 5Y EPS Growth 13.18%
This Y EPS Growth (11.36%) (below 0%: weak)
Next Y EPS Growth 15.55% (at or above 15%: strong)
Next Y revenue growth 38.20% (at or above 10%: strong)
Next 5Y EPS Growth 6.93%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.6×, against a ten-year median of 14.1×; over the ten years it ranged from 4.7× in 2026 to 51.5× in 2021.
P/E against its own 10 years 24.19%
10-year low 10-year high
P/S against its own 10 years 13.03%
10-year low 10-year high
P/B against its own 10 years 32.96%
10-year low 10-year high
EV/Sales against its own 10 years 14.91%
10-year low 10-year high
EV/FCF against its own 10 years 14.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 763 916 749 688
Receivables 101 128 145 178
Inventory — — — —
Other — — — —
913 1,089 944 914
2024 2025 2026 Q'26
Payables 2 1 4 6
ST’ Debt — — — —
Other — — — —
147 156 155 150

Compound Annual Growth %

10y 5y 3y
Sales — 25.53% 15.45%
Cash Flow — 31.52% 22.04%
Earnings — 55.51% 20.23%
Book Value — 45.03% (0.53%)

Revenue $m

Jun Sep Dec Mar Year
’26 157 — — — —
’26 146 169 185 145 645
’25 127 137 169 138 570
’24 108 114 135 118 475
’23 91 102 115 111 419
’22 73 79 98 94 344
’21 36 45 59 67 207
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 42 — — — —
’26 62 94 61 110 326
’25 41 68 65 98 273
’24 57 13 50 64 184
’23 45 40 49 47 180
’22 33 19 27 47 127
’21 9 13 24 38 83
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 40 — — — —
’26 60 92 59 107 317
’25 (131) 237 63 97 267
’24 56 12 49 62 178
’23 43 38 47 46 173
’22 32 18 26 45 121
’21 8 11 23 37 78
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 0.13 — — — —
’26 0.27 0.31 0.31 0.10 0.98
’25 0.21 0.22 0.37 0.31 1.11
’24 0.13 0.15 0.24 0.20 0.72
’23 0.10 0.12 0.16 0.14 0.53
’22 0.09 0.17 0.26 0.16 0.70
’21 0.02 0.11 0.17 0.23 0.53
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low — — — — 41.17 22.91 19.71 22.96 43.25 17.15

Analyst estimates 2027–2029

Powerpack
High — — — — 107.79 64.95 40.12 61.75 85.21 46.75
People
People Employees — — — — 713 887 977 827 830 880
Revenue/emp, $m — — 0.00 0.00 0.29 0.39 0.43 0.57 0.69 0.73
Income, $m
Income, $m Revenue — — 86 116 207 344 419 475 570 645
Gross margin, % — — 87.29 87.20 84.92 88.42 87.24 89.34 90.20 89.09
EBT — — 8 24 58 114 133 185 264 250
EBT margin, % — — 9.25 20.20 27.92 33.18 31.78 38.96 46.21 38.77
Net income — 0 8 30 50 155 113 148 223 196
Depreciation — — 6 6 11 19 22 14 9 20
Per share, $
Per share, $ Revenue — — 1.33 1.74 2.78 2.10 2.17 2.50 3.05 3.45
Earnings — — 0.12 0.45 0.68 0.82 0.58 0.78 1.19 1.05
Cash flow — — 0.24 0.39 1.12 0.77 0.93 0.97 1.46 1.75
Capex — — (0.02) (0.06) (0.06) (0.03) (0.03) (0.03) (0.03) (0.05)
Free cash flow — — 0.22 0.33 1.05 0.74 0.90 0.94 1.43 1.70
Book value — — 0.00 1.24 1.99 5.37 5.00 4.74 5.79 5.08
Shares, m — — 64 67 74 163 193 190 187 187
Valuation, ×
Valuation, × P/E — — 78.47 78.47 78.47 67.91 54.88 33.43 48.76 22.40
P/S — — 19.04 19.04 19.04 24.79 14.93 10.56 19.01 6.76
P/B — — 59.03 59.03 59.03 9.69 6.47 5.57 10.01 4.58
EV/Sales — — 18.36 18.36 18.36 22.46 12.92 8.96 17.40 5.60
EV/FCF — — 48.46 48.46 48.46 63.85 31.22 23.89 37.22 11.36
Cash, $m
Cash, $m Operating cash flow — — 15 26 83 127 180 184 273 326
Capex — — (1) (4) (5) (6) (6) (6) (7) (9)
Free cash flow — — 14 22 78 121 173 178 267 317
Balance, $m
Balance, $m Working capital — — — 67 107 793 836 766 932 789
Total debt — — — 2 1 1 16 — — —
Net debt — — — (86) (143) (798) (841) (763) (916) (749)
Shareholders’ equity — — — 83 148 879 966 901 1,083 951
Returns, %
Returns, % ROA — — 0.00 15.59 11.04 21.44 10.60 13.32 19.05 16.42
ROIC — — 0.00 0.00 587.87 88.17 62.50 73.95 85.27 66.42
ROE — — 0.00 31.91 63.51 28.19 12.23 15.81 22.50 19.28
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Doximity, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TEM Tempus AI, Inc. $12.8B — (loss-making) — (loss-making) +21.56% (above 0%: growing) n/m −153.72% (below 0%: shrinking) 64.45% (19.85%) Compare
BTSG BrightSpring Health Services, Inc. $12.3B 34.0× 37.6× +23.05% (above 0%: growing) +192.86% (above 0%: growing) −39.62% (below 0%: shrinking) 12.72% 3.37% Compare
TXG 10x Genomics $9.4B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
HNGE Hinge Health Inc. $8.5B 73.5× 39.4× +53.00% (above 0%: growing) n/m +441.14% (above 0%: growing) 86.44% 19.00% Compare
HQY HealthEquity, Inc. $7.7B 33.0× 30.2× +7.64% (above 0%: growing) +14.49% (above 0%: growing) −3.44% (below 0%: shrinking) 73.55% 28.14% Compare
DOCS Doximity, Inc. $5.6B 34.8× 26.2× +7.34% (above 0%: growing) −53.57% (below 0%: shrinking) −34.14% (below 0%: shrinking) 84.87% 21.48%
WAY Waystar Holding Corp. $5.4B 38.0× 22.4× +18.11% (above 0%: growing) +10.53% (above 0%: growing) −52.42% (below 0%: shrinking) 69.44% 23.79% Compare
HTFL Heartflow, Inc. $4.4B — (loss-making) — (loss-making) +47.57% (above 0%: growing) n/m +62.62% (above 0%: growing) 83.00% (27.93%) Compare
PRVA Privia Health Group, Inc. $2.9B 102× 87.8× +21.39% (above 0%: growing) +250.00% (above 0%: growing) −86.20% (below 0%: shrinking) 9.93% 1.86% Compare
Median of peers $8.1B 38.0× 37.6× +21.48% +103.68% −22.11% 71.50% 2.62%

All 51 Health Information Services stocks →

Doximity, Inc. (DOCS) key facts

  • Strength: Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025.
  • Doximity, Inc. (DOCS) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, DOCS traded at $30.97, a market capitalization of $5.6 billion.
  • Return on equity was 19.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 17.11 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Doximity, Inc. (DOCS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/DOCS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com